Skip to main content
SpringerLink
Log in
Book cover

Contemporary Treatment of Erectile Dysfunction pp 221–236Cite as

Peyronie’s Disease: Natural History, Diagnosis, and Medical Therapy

  • Chapter
  • First Online:

  • 1023 Accesses

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Peyronie’s disease (PD) is an acquired disorder of the tunica albuginea of the penis resulting in varying degrees of penile curvature and sexual dysfunction. The diagnosis of the disorder is usually straightforward after a detailed sexual history and focused physical exam. Although a wide range of medical treatments have been employed to treat the disorder, data from randomized trials support only a few. The administration of intralesional verapamil has provided generally consistent and positive results, while some evidence exists to support the use of colchicine, Potaba™, l-carnitine, and superoxide dismutase. Other promising therapies, but not yet verified by randomized trials, include penile extender devices and pentoxifylline.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Zargooshi, J. (2004). Trauma as the cause of Peyronie’s disease: penile fracture as a model of trauma. Journal d’Urologie, 172, 186–188.

    Google Scholar 

  2. Taylor, F. L., & Levine, L. A. (2007). Peyronie’s disease. The Urologic Clinics of North America, 34, 517–534.

    Article  PubMed  Google Scholar 

  3. Lindsay, M. B., Schain, D. M., Grambsch, P., Benson, R. C., Beard, C. M., & Kurland, L. T. (1991). The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. Journal d’Urologie, 146, 1007–1009.

    CAS  Google Scholar 

  4. Jordan, G. (2007). Peyronie’s disease. In L. Kavoussi, A. Novick, A. Partin, C. Peters, & A. Wein (Eds.), Campbell-Walsh Urology (Ninthth ed., pp. 818–838). Philadelphia: Saunders Elsevier.

    Google Scholar 

  5. Rhoden, E. L., Teloken, C., Ting, H. Y., & Lucas, M. L. (2001). Teodosio da Ros C, Ary Vargas Souto C. Prevalence of Peyronie’s disease in men over 50-y-old from Southern Brazil. International Journal of Impotence Research, 13, 291–293.

    Article  CAS  PubMed  Google Scholar 

  6. Mulhall, J. P., Creech, S. D., Boorjian, S. A., Ghaly, S., Kim, E. D., Moty, A., et al. (2004). Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. Journal d’Urologie, 171, 2350–2353.

    Google Scholar 

  7. Schwarzer, U., Sommer, F., Klotz, T., Braun, M., Reifenrath, B., & Engelmann, U. (2001). The prevalence of Peyronie’s disease: results of a large survey. BJU International, 88, 727–730.

    Article  CAS  PubMed  Google Scholar 

  8. Kadioglu, A., Oktar, T., Kandirali, E., Kendirci, M., Sanli, O., & Ozsoy, C. (2004). Incidentally diagnosed Peyronie’s disease in men presenting with erectile dysfunction. International Journal of Impotence Research, 16, 540–543.

    Article  CAS  PubMed  Google Scholar 

  9. Mulhall, J. P., Schiff, J., & Guhring, P. (2006). An analysis of the natural history of Peyronie’s disease. Journal d’Urologie, 175, 2115–2118. Discussion 8.

    Google Scholar 

  10. Jordan, G. (2006) Peyronie’s disease. In: W. Campbell (Ed.), Campbell-Walsh Urology.

    Google Scholar 

  11. El-Sakka, A. I., Hassoba, H. M., Pillarisetty, R. J., Dahiya, R., & Lue, T. F. (1997). Peyronie’s disease is associated with an increase in transforming growth factor-beta protein expression. The Journal of Urology, 158, 1391–1394.

    Article  CAS  PubMed  Google Scholar 

  12. Smith, B. H. (1966). Peyronie’s disease. American Journal of Clinical Pathology, 45, 670–678.

    CAS  PubMed  Google Scholar 

  13. Brock, G., Hsu, G. L., Nunes, L., von Heyden, B., & Lue, T. F. (1997). The anatomy of the tunica albuginea in the normal penis and Peyronie’s disease. The Journal of Urology, 157, 276–281.

    Article  CAS  PubMed  Google Scholar 

  14. Devine, C. J., Jr., & Horton, C. E. (1988). Peyronie’s disease. Clinics in Plastic Surgery, 15, 405–409.

    PubMed  Google Scholar 

  15. Lue, T. F. (2002). Peyronie’s disease: an anatomically-based hypothesis and beyond. International Journal of Impotence Research, 14, 411–413.

    Article  CAS  PubMed  Google Scholar 

  16. Akkus, E., Carrier, S., Baba, K., Hsu, G. L., Padma-Nathan, H., Nunes, L., et al. (1997). Structural alterations in the tunica albuginea of the penis: impact of Peyronie’s disease, ageing and impotence. British Journal of Urology, 79, 47–53.

    CAS  PubMed  Google Scholar 

  17. Smith, J. F., Conti, S. L., Shindel, A. W., Walsh, T. J., Eisenberg, M., Brant, W. O., et al. (2008) The incidence and prevalence of sonographic characteristics in men with Peyronie’s disease. Sexual Medicine of Society of North America Annual Meeting 2008; Abstract.

    Google Scholar 

  18. Iacono, F., Barra, S., De Rosa, G., Boscaino, A., & Lotti, T. (1993). Microstructural disorders of tunica albuginea in patients affected by Peyronie’s disease with or without erection dysfunction. The Journal of Urology, 150, 1806–1809.

    CAS  PubMed  Google Scholar 

  19. Somers, K. D., & Dawson, D. M. (1997). Fibrin deposition in Peyronie’s disease plaque. The Journal of Urology, 157, 311–315.

    Article  CAS  PubMed  Google Scholar 

  20. Brant, W. O., Bella, A. J., Garcia, M. M., Tantiwongse, K., Dean, R. C., & Lue, T. F. (2007). Isolated septal fibrosis or hematoma – atypical Peyronie’s disease? Journal d’Urologie, 177, 179–182. Discussion 83.

    Google Scholar 

  21. Hellstrom, W. J., & Bivalacqua, T. J. (2000). Peyronie’s disease: etiology, medical, and surgical therapy. Journal of Andrology, 21, 347–354.

    CAS  PubMed  Google Scholar 

  22. El-Sakka, A. I., Hassoba, H. M., Chui, R. M., Bhatnagar, R. S., Dahiya, R., & Lue, T. F. (1997). An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. The Journal of Urology, 158, 2284–2290.

    Article  CAS  PubMed  Google Scholar 

  23. Davila, H. H., Magee, T. R., Zuniga, F. I., Rajfer, J., & Gonzalez-Cadavid, N. F. (2005). Peyronie’s disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology, 65, 645–648.

    Article  PubMed  Google Scholar 

  24. Qian, A., Meals, R., & Rajfer, J. (2004). Comparison of Gene Expression Profiles between Peyronie’s disease and Dupuytren’s contracture. Urology, 64, 399–404.

    Article  CAS  PubMed  Google Scholar 

  25. Afsar, H., & Sozduyar, N. (1992). Urethral manipulation syndrome (Kelami syndrome): acquired ventral penile deviation. Archivio Italiano di Urologia, Nefrologia, Andrologia, 64, 349–351.

    CAS  PubMed  Google Scholar 

  26. Kelami, A. (1984). Urethral manipulation syndrome. Description of a new syndrome. Urologia internationalis, 39, 352–354.

    Article  CAS  PubMed  Google Scholar 

  27. Merkle, W. (1990). Cause of deviation of the erectile penis after urethral manipulations (Kelami syndrome)–demonstration of ultrasound findings and case reports. Urologia Internationalis, 45, 183–185.

    Article  CAS  PubMed  Google Scholar 

  28. Lyles, K. W., Gold, D. T., Newton, R. A., Parekh, S., Shipp, K. M., Pieper, C. F., et al. (1997). Peyronie’s disease is associated with Paget’s disease of bone. Journal of Bone and Mineral Research, 12, 929–934.

    Article  CAS  PubMed  Google Scholar 

  29. Smith, J. F., Walsh, T. J., Conti, S. L., Turek, P., & Lue, T. (2008). Risk factors for emotional and relationship problems in Peyronie’s disease. The Journal of Sexual Medicine, 5, 2179–2184.

    Article  PubMed  Google Scholar 

  30. Jordan, G. H., & Angermeier, K. W. (1993). Preoperative evaluation of erectile function with dynamic infusion cavernosometry/cavernosography in patients undergoing surgery for Peyronie’s disease: correlation with postoperative results. Journal d’Urologie, 150, 1138–1142.

    CAS  Google Scholar 

  31. Ralph, D. J., Hughes, T., Lees, W. R., & Pryor, J. P. (1992). Pre-operative assessment of Peyronie’s disease using colour Doppler sonography. British Journal of Urology, 69, 629–632.

    Article  CAS  PubMed  Google Scholar 

  32. Jarow, J. P., & Lowe, F. C. (1997). Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. Journal d’Urologie, 158, 1388–1390.

    CAS  Google Scholar 

  33. Deveci, S., Palese, M., Parker, M., Guhring, P., & Mulhall, J. P. (2006). Erectile function profiles in men with Peyronie’s disease. Journal d’Urologie, 175, 1807–1811. Discussion 11.

    Google Scholar 

  34. Kendirci, M., Trost, L., Sikka, S. C., & Hellstrom, W. J. (2007). Diabetes mellitus is associated with severe Peyronie’s disease. BJU International, 99, 383–386.

    Article  PubMed  Google Scholar 

  35. Rosen, R., Catania, J., Lue, T., Althof, S., Henne, J., Hellstrom, W., et al. (2008). Impact of Peyronie’s disease on sexual and psychosocial functioning: qualitative findings in patients and controls. The Journal of Sexual Medicine, 5, 1977–1984.

    Article  PubMed  Google Scholar 

  36. Nelson, C. J., Diblasio, C., Kendirci, M., Hellstrom, W., Guhring, P., & Mulhall, J. P. (2008). The chronology of depression and distress in men with Peyronie’s disease. The Journal of Sexual Medicine, 5, 1985–1990.

    Article  PubMed  Google Scholar 

  37. Levine, L. A., & Greenfield, J. M. (2003). Establishing a standardized evaluation of the man with Peyronie’s disease. International Journal of Impotence Research, 15(Suppl 5), S103–S112.

    Article  PubMed  Google Scholar 

  38. Ohebshalom, M., Mulhall, J., Guhring, P., & Parker, M. (2007). Measurement of penile curvature in Peyronie’s disease patients: comparison of three methods. The Journal of Sexual Medicine, 4, 199–203.

    Article  PubMed  Google Scholar 

  39. Donatucci, C. F., & Lue, T. F. (1992). Correction of penile deformity assisted by intracavernous injection of papaverine. Journal d’Urologie, 147, 1108–1110.

    CAS  Google Scholar 

  40. Andresen, R., Wegner, H. E., Miller, K., & Banzer, D. (1998). Imaging modalities in Peyronie’s disease. An intrapersonal comparison of ultrasound sonography, X-ray in mammography technique, computerized tomography, and nuclear magnetic resonance in 20 patients. European Urology, 34, 128–134. Discussion 35.

    Article  CAS  PubMed  Google Scholar 

  41. Hauck, E. W., Hackstein, N., Vosshenrich, R., Diemer, T., Schmelz, H. U., Bschleipfer, T., et al. (2003). Diagnostic value of magnetic resonance imaging in Peyronie’s disease – a comparison both with palpation and ultrasound in the evaluation of plaque formation. European Urology, 43, 293–299. Discussion 9–300.

    Article  PubMed  Google Scholar 

  42. Aversa, A., & Sarteschi, L. M. (2007). The role of penile color-duplex ultrasound for the evaluation of erectile dysfunction. The Journal of Sexual Medicine, 4, 1437–1447.

    Article  PubMed  Google Scholar 

  43. Lee, R. C., & Ping, J. A. (1990). Calcium antagonists retard extracellular matrix production in connective tissue equivalent. The Journal of Surgical Research, 49, 463–466.

    Article  CAS  PubMed  Google Scholar 

  44. Rehman, J., Benet, A., & Melman, A. (1998). Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology, 51, 620–626.

    Article  CAS  PubMed  Google Scholar 

  45. Cavallini, G., Biagiotti, G., Koverech, A., & Vitali, G. (2002). Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie’s disease. BJU International, 89, 895–900.

    Article  CAS  PubMed  Google Scholar 

  46. Cavallini, G., Modenini, F., & Vitali, G. (2007). Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie’s disease. Urology, 69, 950–954.

    Article  PubMed  Google Scholar 

  47. Russell, S., Steers, W., & McVary, K. T. (2007). Systematic evidence-based analysis of plaque injection therapy for Peyronie’s disease. European Urology, 51, 640–647.

    Article  PubMed  Google Scholar 

  48. Jordan, G. H. (2008). The use of intralesional clostridial collagenase injection therapy for Peyronie’s disease: a prospective, single-center, non-placebo-controlled study. The Journal of Sexual Medicine, 5, 180–187.

    Article  PubMed  Google Scholar 

  49. Gelbard, M. K., Lindner, A., & Kaufman, J. J. (1985). The use of collagenase in the treatment of Peyronie’s disease. Journal d’Urologie, 134, 280–283.

    CAS  Google Scholar 

  50. Duncan, M. R., Hasan, A., & Berman, B. (1995). Pentoxifylline, pentifylline, and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. The Journal of Investigative Dermatology, 104, 282–286.

    Article  CAS  PubMed  Google Scholar 

  51. Duncan, M. R., Berman, B., & Nseyo, U. O. (1991). Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scandinavian Journal of Urology and Nephrology, 25, 89–94.

    Article  CAS  PubMed  Google Scholar 

  52. Inal, T., Tokatli, Z., Akand, M., Ozdiler, E., & Yaman, O. (2006). Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie’s disease: a randomized and prospective study. Urology, 67, 1038–1042.

    Article  PubMed  Google Scholar 

  53. Hellstrom, W. J., Kendirci, M., Matern, R., Cockerham, Y., Myers, L., Sikka, S. C., et al. (2006). Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. Journal d’Urologie, 176, 394–398.

    CAS  Google Scholar 

  54. Bartsch, G., Menander-Huber, K. B., Huber, W., & Marberger, H. (1981). Orgotein, a new drug for the treatment of Peyronie’s disease. European Journal of Rheumatology and Inflammation, 4, 250–259.

    CAS  PubMed  Google Scholar 

  55. Gustafson, H., Johansson, B., & Edsmyr, F. (1981). Peyronie’s disease: experience of local treatment with Orgotein. European Urology, 7, 346–348.

    CAS  PubMed  Google Scholar 

  56. Montorsi, F., Salonia, A., Guazzoni, G., Barbieri, L., Colombo, R., Brausi, M., et al. (2000). Transdermal electromotive multi-drug administration for Peyronie’s disease: preliminary results. Journal of Andrology, 21, 85–90.

    CAS  PubMed  Google Scholar 

  57. Riedl, C. R., Sternig, P., Galle, G., Langmann, F., Vcelar, B., Vorauer, K., et al. (2005). Liposomal recombinant human superoxide dismutase for the treatment of Peyronie’s disease: a randomized placebo-controlled double-blind prospective clinical study. European Urology, 48, 656–661.

    Article  CAS  PubMed  Google Scholar 

  58. Di Stasi, S. M., Giannantoni, A., Stephen, R. L., Capelli, G., Giurioli, A., Jannini, E. A., et al. (2004). A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. Journal d’Urologie, 171, 1605–1608.

    Google Scholar 

  59. Greenfield, J. M., Shah, S. J., & Levine, L. A. (2007). Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. Journal d’Urologie, 177, 972–975.

    CAS  Google Scholar 

  60. Fitch, W. P., 3rd, Easterling, W. J., Talbert, R. L., Bordovsky, M. J., & Mosier, M. (2007). Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease–a placebo-controlled pilot study. The Journal of Sexual Medicine, 4, 477–484.

    Article  CAS  PubMed  Google Scholar 

  61. Martin, D. J., Badwan, K., Parker, M., & Mulhall, J. P. (2002). Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. Journal d’Urologie, 168, 2483–2485.

    CAS  Google Scholar 

  62. Bremer, J. (1983). Carnitine–metabolism and functions. Physiological Reviews, 63, 1420–1480.

    CAS  PubMed  Google Scholar 

  63. Biagiotti, G., & Cavallini, G. (2001). Acetyl-l-carnitine vs tamoxifen in the oral therapy of Peyronie’s disease: a preliminary report. BJU International, 88, 63–67.

    Article  CAS  PubMed  Google Scholar 

  64. Safarinejad, M. R., Hosseini, S. Y., & Kolahi, A. A. (2007). Comparison of vitamin E and propionyl-l-carnitine, separately or in combination, in patients with early chronic Peyronie’s disease: a double-blind, placebo controlled, randomized study. Journal d’Urologie, 178, 1398–1403. Discussion 403.

    CAS  Google Scholar 

  65. Karlic, H., & Lohninger, A. (2004). Supplementation of l-carnitine in athletes: does it make sense? Nutrition, 20, 709–715. Burbank, Los Angeles County, Calif.

    Article  CAS  PubMed  Google Scholar 

  66. Wagenknecht, L. V. (1996). Differential therapies in various stages of penile induration. Archivos Españoles de Urología, 49, 285–292.

    CAS  PubMed  Google Scholar 

  67. Carson, C. C. (1997). Potassium para-aminobenzoate for the treatment of Peyronie’s disease: is it effective? Techniques in Urology, 3, 135–139.

    CAS  PubMed  Google Scholar 

  68. Weidner, W., Hauck, E. W., & Schnitker, J. (2005). Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. European Urology, 47, 530–535. Discussion 5–6.

    Article  CAS  PubMed  Google Scholar 

  69. McCarty, M. F. (1999). Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Medical Hypotheses, 52, 465–477.

    Article  CAS  PubMed  Google Scholar 

  70. Delanian, S., Porcher, R., Balla-Mekias, S., & Lefaix, J. L. (2003). Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. Journal of Clinical Oncology, 21, 2545–2550.

    Article  CAS  PubMed  Google Scholar 

  71. Tittelbach, J., Graefe, T., & Wollina, U. (2001). Painful ulcers in calciphylaxis – combined treatment with maggot therapy and oral pentoxyfillin. The Journal of Dermatological Treatment, 12, 211–214.

    Article  CAS  PubMed  Google Scholar 

  72. Boldt, J., Brosch, C., Lehmann, A., Haisch, G., Lang, J., & Isgro, F. (2001). Prophylactic use of pentoxifylline on inflammation in elderly cardiac surgery patients. The Annals of Thoracic Surgery, 71, 1524–1529.

    Article  CAS  PubMed  Google Scholar 

  73. Aygenc, E., Celikkanat, S., Kaymakci, M., Aksaray, F., & Ozdem, C. (2004). Prophylactic effect of pentoxifylline on radiotherapy complications: a clinical study. Otolaryngology: Head and Neck Surgery, 130, 351–356.

    Article  Google Scholar 

  74. Boldt, J., Brosch, C., Piper, S. N., Suttner, S., Lehmann, A., & Werling, C. (2001). Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Critical Care Medicine, 29, 952–958.

    Article  CAS  PubMed  Google Scholar 

  75. Noel, C., Copin, M. C., Hazzan, M., Labalette, M., Susen, S., Lelievre, G., et al. (2000). Immunomodulatory effect of pentoxifylline during human allograft rejection: involvement of tumor necrosis factor-alpha and adhesion molecules. Transplantation, 69, 1102–1107.

    Article  CAS  PubMed  Google Scholar 

  76. Valente, E. G., Vernet, D., Ferrini, M. G., Qian, A., Rajfer, J., & Gonzalez-Cadavid, N. F. (2003). l-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide, 9, 229–244.

    Article  CAS  PubMed  Google Scholar 

  77. Takami, M., Cho, E. S., Lee, S. Y., Kamijo, R., & Yim, M. (2005). Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Letters, 579, 832–838.

    Article  CAS  PubMed  Google Scholar 

  78. Rajfer, J., Gore, J. L., Kaufman, J., & Gonzalez-Cadavid, N. (2006). Case report: Avoidance of palpable corporal fibrosis due to priapism with upregulators of nitric oxide. The Journal of Sexual Medicine, 3, 173–176.

    Article  PubMed  Google Scholar 

  79. Brant, W. O., Dean, R. C., & Lue, T. F. (2006). Treatment of Peyronie’s disease with oral pentoxifylline. Nature Clinical Practice Urology, 3, 111–115. quiz 6.

    Article  PubMed  Google Scholar 

  80. Pentoxifylline: Adverse Effects. Thomson. (2008). Retrieved March 15, 2008 from http://www.ucsf.som.edu/micromedex.

  81. Trost, L. W., Gur, S., & Hellstrom, W. J. (2007). Pharmacological management of Peyronie’s disease. Drugs, 67, 527–545.

    Article  CAS  PubMed  Google Scholar 

  82. Azzi, A. (2007). Molecular mechanism of alpha-tocopherol action. Free Radical Biology and Medicine, 43, 16–21.

    Article  CAS  PubMed  Google Scholar 

  83. Prieto Castro, R. M., Leva Vallejo, M. E., Regueiro Lopez, J. C., Anglada Curado, F. J., Alvarez Kindelan, J., & Requena Tapia, M. J. (2003). Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU International, 91, 522–524.

    Article  CAS  PubMed  Google Scholar 

  84. Brigelius-Flohe, R. (2007). Adverse effects of vitamin E by induction of drug metabolism. Genes and Nutrition, 2, 249–256.

    Article  CAS  PubMed  Google Scholar 

  85. Colletta, A. A., Wakefield, L. M., Howell, F. V., van Roozendaal, K. E., Danielpour, D., Ebbs, S. R., et al. (1990). Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. British Journal of Cancer, 62, 405–409.

    CAS  PubMed  Google Scholar 

  86. Hauck, E. W., Diemer, T., Schmelz, H. U., & Weidner, W. (2006). A critical analysis of nonsurgical treatment of Peyronie’s disease. European Urology, 49, 987–997.

    Article  CAS  PubMed  Google Scholar 

  87. Teloken, C., Rhoden, E. L., Grazziotin, T. M., Ros, C. T., Sogari, P. R., & Souto, C. A. (1999). Tamoxifen versus placebo in the treatment of Peyronie’s disease. Journal d’Urologie, 162, 2003–2005.

    CAS  Google Scholar 

  88. Diegelmann, R. F., & Peterkofsky, B. (1972). Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. Proceedings of the National Academy of Sciences of the United States of America, 69, 892–896.

    Article  CAS  PubMed  Google Scholar 

  89. Cannella, A. C., & Mikuls, T. R. (2005). Understanding treatments for gout. The American Journal of Managed Care, 11, S451–S458. quiz S65-8.

    PubMed  Google Scholar 

  90. Safarinejad, M. R. (2004). Therapeutic effects of colchicine in the management of Peyronie’s disease: a randomized double-blind, placebo-controlled study. International Journal of Impotence Research, 16, 238–243.

    Article  CAS  PubMed  Google Scholar 

  91. Gontero, P., Di Marco, M., Giubilei, G., Tizzani, A., Fontana, F., & Bartoletti, N. (2009). Use of penile extender device in the treatment of penile curvature due to Peyronie’s disease. Results of a phase II prospective study. The Journal of Sexual Medicine, 6, 558–6.

    Article  PubMed  Google Scholar 

  92. Levine, L. A., Newell, M., & Taylor, F. L. (2008). Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. The Journal of Sexual Medicine, 5, 1468–1473.

    Article  PubMed  Google Scholar 

  93. Claro, J. A., Passerotti, C. C., Figueiredo Neto, A. C., Nardozza, A., Jr., Ortiz, V., & Srougi, M. (2004). An alternative non-invasive treatment for Peyronie’s disease. International Brazilian Journal of Urology, 30, 199–204. Discussion.

    PubMed  Google Scholar 

  94. Abdel-Salam, Y., Budair, Z., Renner, C., Frede, T., Rassweiler, J., El-Annany, F., et al. (1999). Treatment of Peyronie’s disease by extracorporeal shockwave therapy: evaluation of our preliminary results. Journal of endourology/Endourological Society, 13, 549–552.

    Article  CAS  PubMed  Google Scholar 

  95. Skolarikos, A., Alargof, E., Rigas, A., Deliveliotis, C., & Konstantinidis, E. (2005). Shockwave therapy as first-line treatment for Peyronie’s disease: a prospective study. Journal of endourology/Endourological Society, 19, 11–14.

    Article  CAS  PubMed  Google Scholar 

  96. Hatzichristodoulou, G., Meisner, C., Liske, P., Stenzl, A., & Lahme, S. (2006). Efficacy of extracorporeal shock wave therapy (ESWT) in patients with Peyronie’s disease (PD)-first results of a prospective, randomized, placebo-controlled, single-blind study. The Journal of Urology, 175, 320.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA, 94143-1695, USA

    James F. Smith

Authors
  1. James F. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William O. Brant
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tom F. Lue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James F. Smith .

Editor information

Editors and Affiliations

  1. Feinberg School of Medicine, Department of Urology, Northwestern University, East Chicago Avenue 303, Chicago, 60611-3008, Illinois, USA

    Kevin T. McVary

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Smith, J.F., Brant, W.O., Lue, T.F. (2011). Peyronie’s Disease: Natural History, Diagnosis, and Medical Therapy. In: McVary, K. (eds) Contemporary Treatment of Erectile Dysfunction. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-60327-536-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-536-1_16

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-535-4

  • Online ISBN: 978-1-60327-536-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation